-
Quality upgrade, live up to trust, help ITP patients live at ease
Time of Update: 2021-10-10
Primary immune thrombocytopenia (primary immune thrombocytopenia, ITP) is an acquired autoimmune disease characterized by thrombocytopenia, and one of the most common clinical bleeding diseases [1] .
-
Blood: Compared with CAR-T therapy, auto-HCT is more suitable as a consolidation treatment for DLCLC patients who have achieved partial remission!
Time of Update: 2021-10-10
LymphomaAt present, the relative efficacy of autologous hematopoietic stem cell transplantation (auto-HCT) and chimeric antigen receptor T cell (CAR-T) therapy as consolidation therapy for DLBCL patients who have achieved partial remission (PR) after salvage chemotherapy is still unclear.
-
J Clin Oncol: The prognosis of DA-EPOCH-R regimen in the treatment of primary mediastinal large B-cell lymphoma in children and adolescents
Time of Update: 2021-10-10
Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial .
-
BJH: Early use of corticosteroids for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma
Time of Update: 2021-10-10
In conclusion, by down-regulating key pro-inflammatory soluble serum biomarkers (including cytokines), earlier and targeted use of corticosteroids and/or tocilizumab may reduce the incidence of grade 3 CRS and NE without It will significantly affect the expansion of CAR T cells and the remission rate of R/R LBCL patients who continue to receive axi-cel treatment .
-
BJHaem: TEAD4 regulates the suppression of fetal hemoglobin by directly binding to the γ-globulin gene promoter
Time of Update: 2021-10-10
TEA domain transcription factor 4 (TEAD4) inhibits induced β- The expression of γ-globulin (HBG) in thalassemia CD34+ and HUDEP-2 cells Figure 2.
TEA domain transcription factor 4 (TEAD4) inhibits induced β- The expression of γ-globulin (HBG) in thalassemia CD34+ and HUDEP-2 cells Figure 2.
-
BJH: The effect of donor telomere length on the survival rate of sibling donor transplant patients with aplastic anemia
Time of Update: 2021-10-09
In the multivariate analysis, the longer donor telomere length, recipient age and acute graft-versus-host disease remained severe .
Graft versus host disease is still serious This is the first study to study the effect of donor and recipient telomere length on the transplant outcome of AAMSD transplant patients .
-
In-depth analysis of WuXi Junuo CAR-T therapy product Ruijilunsai injection for the first time globally
Time of Update: 2021-10-02
announced its CD19-targeting autologous chimeric antigen receptor T (CAR-T) cellular immunotherapy product Benoda (Reiki Orenza Injection, The development code JWCAR029) was approved for marketing by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) after second-line or above systemic treatment .
-
Express develops tumor-infiltrating lymphocyte therapy to treat solid tumors, Xinrui receives US$115 million in assistance
Time of Update: 2021-10-02
The funds obtained in this round of financing will be used to promote Obsidian's main tumor infiltrating lymphocyte (TIL) project cytoTIL15 into the clinic to obtain the first batch of clinical trial data for the treatment of metastatic melanoma .
-
Professor Liu Jiajun talks about the treatment progress of primary central nervous system lymphoma (part 1)
Time of Update: 2021-10-02
High-dose methotrexate (HD-MTX) with or without whole brain radiation therapy (WBRT) is the most effective treatment .
In previous studies, the use of WBRT (36-40Gy) as the only treatment for PCNSL resulted in an overall response rate (ORR) of 90%, but the median overall survival (OS) was only 11.
-
Early and first-line initiation of Rucotinib treatment has significant benefits
Time of Update: 2021-10-02
The final result of this analysis was published online in Leuk Lymphoma in 2020, consistent with the report of the 2018 EHA conference, early (medium risk-1/low risk), first-line Initiating rucotinib treatment and maintaining sufficient rucotinib treatment can achieve a higher splenic response rate [4] .
-
Professor Liu Jiajun talks about the treatment progress of primary central nervous system lymphoma (part 2)
Time of Update: 2021-10-02
, High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study.
, [Clinical Efficacy of High Dose Methotrexate, Temozolomide and Rituximab in the Treatment of Patients with Primary Central Nervous System Lymphoma].
-
2021 IMW carfilzomib combination regimen in the treatment of multiple myeloma
Time of Update: 2021-10-02
Abstract OAB-003: Sequential Carfilzomib maintenance treatment in newly diagnosed MM patients receiving ASCT or KCd regimen consolidation treatment: CARDAMON study results Research background Newly diagnosed multiple myeloma (NDMM) patients reached minimal residual disease after induction and consolidation treatment (MRD) is negative, whether it is necessary to receive autologous hematopoietic stem cell transplantation (ASCY) is not yet clear .
-
2021 IMW BCMA CAR-T therapy cilta-cel treatment of MM research results update
Time of Update: 2021-10-02
Research conclusions At a median follow-up of 18 months, cilta-cel achieved early, lasting and deep disease remission in patients with relapsed and refractory MM, and its safety was controllable .
Research conclusions Cilta-cel has achieved early and deep disease remission in MM patients with controllable safety .
-
"No pain, no disability", domestic recombinant human coagulation factor Ⅷ brings new hope to Chinese hemophilia patients!
Time of Update: 2021-10-02
Professor Yang Renchi said: "For the challenges that clinicians face in the diagnosis, treatment and management of hemophilia, from From my personal point of view, it is still the issue of patients paying for medical expenses .
-
Professor Liu Jiajun talks about the treatment progress of primary central nervous system lymphoma (medium)
Time of Update: 2021-10-02
The use of hematopoietic stem cell transplantation high-dose chemotherapy combined with autologous stem cell transplantation (HDC-ASCT) in PCNSL has attracted more and more attention, and is often used as the main salvage treatment for patients with relapsed and refractory disease .
-
[Heavyweight] Scientists at Johns Hopkins University have discovered that the self-correction function of genes can resist blood cancer, which is expected to be a major breakthrough in the treatment of blood cancer!
Time of Update: 2021-10-02
Recently, a new study conducted by scientists at Johns Hopkins University has discovered that the genes in the "chromosome cap" can fight gene mutations through self-correcting functions, thereby helping to fight against blood cancer .
-
Professor Zhang Huilai: Theory and practice of PD-1 monoclonal antibody combination therapy in the field of hematology and tumors
Time of Update: 2021-10-02
3. The study of immune checkpoint inhibitor combined with monoclonal antibody/antibody conjugate drug CheckMate 436 showed that in R/R PMBCL patients, the ORR evaluated by the investigator of nivolumab combined with BV treatment reached 70%, and the CR rate was 43 % .
-
Express treatment of acute myeloid leukemia, CRISPR-edited stem cell therapy obtained FDA fast track qualification
Time of Update: 2021-10-02
▎ WuXi AppTec content team editor September 9, 2021, Vor Biopharma announced that the US FDA has granted its engineered hematopoietic stem cell (eHSC) candidate drug VOR33 fast track qualification for the treatment of acute myeloid leukemia (AML) .
-
Boya Ji completes the initiation of Phase I clinical trial for the treatment of β-thalassemia gene editing therapy and the first patient enrolled in the group, Dr. Mai Meng broke the news
Time of Update: 2021-10-02
Recent popular reports from Yimaike ★NoticeShanghai Minhang Biopharmaceutical Industry Development Conference and 2021 Life and Health Industry Summit Forum is about to open in Shanghai ★September·Sh
-
Inventory of research progress on the new mechanism drug Asciminib for chronic myeloid leukemia
Time of Update: 2021-10-02
ATP-competitive tyrosine kinase inhibitor (TKI) targeting BCR-ABL1 is the main drug for the treatment of chronic myeloid leukemia (CML) .
Background Although the use of ATP-competitive TKI targeting BCR-ABL1 has greatly improved the long-term survival outcomes of CML patients, there are still some patients who develop drug resistance and/or intolerance and require dressing changes (Table 1) .
